| Name | Title | Contact Details |
|---|
Vous trouverez chez TruckStore un large choix de camions doccasion, de remorques et de semi-remorques de toutes marques, types, superstructures et âges – vous bénéficierez sur tous les sites européens des mêmes conseils professionnels et dune vaste offre de services en lien avec lachat de votre camion. La Garantie TruckStore absolument unique est un exemple parmi tant dautres de notre éventail de prestations.
Midland States Bank is a community-based financial institution with over a century of history. As a subsidiary of Midland States Bancorp, Inc., headquartered in Effingham, Illinois, the bank is dedicated to supporting local businesses and residents. The bank offers a wide range of financial services, including commercial banking tailored for local businesses, wealth management with a focus on financial planning and investment services, and personal banking solutions that cater to individual needs. Midland States Bank emphasizes a personalized approach, aiming to be a supportive partner for customers during important life events. With a commitment to teamwork and community support, Midland States Bank promotes sustainable practices and social responsibility through its Environmental, Social, and Governance (ESG) initiatives. The bank continues to evolve under the leadership of CEO Leon J. Holschbach, focusing on enhancing profitability and competitiveness in the financial sector.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Public Risk Innovation, Solutions, and Management, PRISM, is a member-directed risk sharing pool of counties and public entities committed to providing risk coverage programs and risk management services.